Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Reading the 10K, I'm more excited about Qapzola. Whereas regarding the patent, it states

EOQUIN: The U.S. formulation patent does not expire until 2022, and method of treatment of bladder cancer using a stabilized formulation that does not expire until 2024. Formulation patents outside the U.S. are due to expire in 2022. We have filed and plan to file additional U.S. and foreign patent applications covering new formulations and/or uses for this product

BUT under 'Product Exclusivity' it states

Under the Hatch-Waxman Act, drug products are provided exclusivity whereby the FDA will not accept applications to market a generic form of an innovator reference listed drug product until the end of the prescribed period. A product is granted a five-year period of exclusivity if it contains a chemical entity never previously approved by the FDA either alone or in combination

So no matter what goes on with patent extensions, Qapzola is guaranteed 5 year 'Product Exclusivity'